{"title":"Outcomes of early-stage oropharyngeal squamous cell carcinoma patients treated with radical radiation - a single institution experience.","authors":"Zuzaki Shabin, Rejnish Kumar, Malu Rafi, Lekha M Nair, Krishnapriya Pisharody, Nijo Jose, Indu Sasikumar, John Mathew, Kumara Pillai Mohanan Nair, Kainickal Cessal Thommachan","doi":"10.3332/ecancer.2025.1901","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Treatment options for early-stage oropharyngeal squamous cell carcinomas (OPSCC) (Stages I and II) include definitive radiation or surgery. This retrospective study aims to evaluate the outcomes of early-stage (Stages I and II) OPSCC treated with radical radiation.</p><p><strong>Materials and methods: </strong>The data of patients with early-stage OPSCC (T1/T2N0) treated with definitive radiation at the Regional Cancer Center, Trivandrum, Kerala, India, from 1st January 2015 to 31st December 2020 were retrieved from medical records. A structured proforma was used to gather clinical and therapeutic details of the patients. The primary objective was to assess loco-regional control and patterns of relapse. Secondary objectives were to assess overall survival (OS), disease-free survival (DFS) and prognostic factors affecting the treatment outcomes. DFS and OS were generated using Kaplan-Meier Curves. The prognostic factors affecting the outcomes were analysed using the Cox-proportional hazards regression model.</p><p><strong>Results: </strong>One hundred and twelve patients with early-stage oropharyngeal cancers who received definitive radiation were included in the study. The majority (91.97%) were males and 90% (101) of the patients had tobacco and alcohol-related habits. Twenty-six (23.3%) among the 112 patients had stage I disease and 86 (76.7%) had stage II disease. The median age group of the study population was 62 years. The most commonly affected primary site was the tonsil (<i>N</i> = 38, 33.9%), followed by the soft palate (<i>N</i> = 34, 30.3%) and followed by the base of the tongue (<i>N</i> = 23, 20.5%). The majority of the patients (80.4% (<i>N</i> = 90)) received a radiotherapy (RT) dose of 60 Gy in 26 fractions at 2.3 Gy per fraction over 5.5 weeks. One hundred nine (97.3%) patients attained remission at 12 weeks following radiation. Three patients had residual disease and none of them underwent salvage surgery. Twenty-one percent (<i>N</i> = 24) of patients had relapsed and the median time to relapse was 20 months. Among the relapses, 7 (29%) underwent salvage surgery and others were given palliative treatment. The most frequent site of relapse was the primary site followed by regional nodes. At a median follow-up of 63 months, the 4-year DFS was 67.9% and OS was 75%. Stage-wise 4-year DFS and OS for stages 1 and II were 68.1% and 64.1%, 78.9% and 73.8%, respectively. The locoregional relapse-free survival at 4 years was 75.2%. Five patients developed a second malignancy and the lung was the most common site. In univariate analysis, age was the only significant prognostic factor that affected the treatment outcomes.</p><p><strong>Conclusion: </strong>The survival outcomes of the patients treated with definitive RT are comparable with the published literature. However, the salvage rates were very poor.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1901"},"PeriodicalIF":1.2000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149235/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2025.1901","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Treatment options for early-stage oropharyngeal squamous cell carcinomas (OPSCC) (Stages I and II) include definitive radiation or surgery. This retrospective study aims to evaluate the outcomes of early-stage (Stages I and II) OPSCC treated with radical radiation.
Materials and methods: The data of patients with early-stage OPSCC (T1/T2N0) treated with definitive radiation at the Regional Cancer Center, Trivandrum, Kerala, India, from 1st January 2015 to 31st December 2020 were retrieved from medical records. A structured proforma was used to gather clinical and therapeutic details of the patients. The primary objective was to assess loco-regional control and patterns of relapse. Secondary objectives were to assess overall survival (OS), disease-free survival (DFS) and prognostic factors affecting the treatment outcomes. DFS and OS were generated using Kaplan-Meier Curves. The prognostic factors affecting the outcomes were analysed using the Cox-proportional hazards regression model.
Results: One hundred and twelve patients with early-stage oropharyngeal cancers who received definitive radiation were included in the study. The majority (91.97%) were males and 90% (101) of the patients had tobacco and alcohol-related habits. Twenty-six (23.3%) among the 112 patients had stage I disease and 86 (76.7%) had stage II disease. The median age group of the study population was 62 years. The most commonly affected primary site was the tonsil (N = 38, 33.9%), followed by the soft palate (N = 34, 30.3%) and followed by the base of the tongue (N = 23, 20.5%). The majority of the patients (80.4% (N = 90)) received a radiotherapy (RT) dose of 60 Gy in 26 fractions at 2.3 Gy per fraction over 5.5 weeks. One hundred nine (97.3%) patients attained remission at 12 weeks following radiation. Three patients had residual disease and none of them underwent salvage surgery. Twenty-one percent (N = 24) of patients had relapsed and the median time to relapse was 20 months. Among the relapses, 7 (29%) underwent salvage surgery and others were given palliative treatment. The most frequent site of relapse was the primary site followed by regional nodes. At a median follow-up of 63 months, the 4-year DFS was 67.9% and OS was 75%. Stage-wise 4-year DFS and OS for stages 1 and II were 68.1% and 64.1%, 78.9% and 73.8%, respectively. The locoregional relapse-free survival at 4 years was 75.2%. Five patients developed a second malignancy and the lung was the most common site. In univariate analysis, age was the only significant prognostic factor that affected the treatment outcomes.
Conclusion: The survival outcomes of the patients treated with definitive RT are comparable with the published literature. However, the salvage rates were very poor.